Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension
Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026 In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high…